26 completed, 6 terminated, 6 unknown, 5 recruiting. 48 Phase 1, 33 Phase 2.
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Psilocybin for Amblyopia - Targeting Critical Periods in Humans Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin - Amblyopia | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 24 | 2026-11-01 | 2026-11-05 |
| Valproate for the Treatment of Residual Amblyopia Valproate, Placebo, Patch - Amblyopia, Amblyopia Unilateral | Phase 1 / Phase 2 | Recruiting | Boston Children's Hospital | 28 | 2026-07-01 | 2026-07-30 |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| BF844 Safety and Pharmacokinetic Study in Healthy Volunteers BF844 - Usher Syndrome Type 3 | Phase 1 | Unknown | EyeXCel Pty. Ltd. | 76 | 2024-09-09 | 2024-09-19 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2025-05-02 |
| Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. Eyecyte-RPE™ - Retinal Disease, Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Eyestem Research Pvt. Ltd. | 54 | 2024-06-04 | 2024-09-24 |
| Docosahexaenoic Acid (DHA) Supplementation in Amblyopia Docosahexaenoic Acid, Placebo Oral Tablet - Amblyopia | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2024-01-01 | 2024-02-09 | |
| Socially Assistive Robots to Enhance Magnification Device Use for Reading Socially Assistive Robot for Low Vision Rehabilitation - Low Vision | Phase 1 | Unknown | University of California, Los Angeles | 20 | 2022-04-22 | 2024-07-19 |
| Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia Binocular video games, Patching of the sound eye - Amblyopia | Phase 1 | Terminated | Novartis Pharmaceuticals | 27 | 2021-06-30 | 2023-05-23 |
| Patient-centered Modular CBT for CPTSD: A Randomised Controlled Pilot Study Psychotherapy - Complex Post-Traumatic Stress Disorder | Phase 1 / Phase 2 | Completed | Danish Veterans Centre | 60 | 2021-01-05 | 2025-04-02 |
| Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome NPI-001, Placebo - Usher Syndromes | Phase 1 / Phase 2 | Completed | Nacuity Pharmaceuticals, Inc. | 49 | 2020-09-03 | 2026-07-01 |
| A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene QR-1123, Sham procedure - Autosomal Dominant Retinitis Pigmentosa, Eye Diseases | Phase 1 / Phase 2 | Active not recruiting | ProQR Therapeutics | 11 | 2019-10-07 | 2022-05-06 |
| Single Ascending Dose Study in Participants With LCA10 EDIT-101 - Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies | Phase 1 / Phase 2 | Unknown | Editas Medicine, Inc. | 34 | 2019-09-26 | 2022-12-05 |
| Gene Therapy for Achromatopsia (CNGA3) adeno-associated virus vector AAV- CNGA3 - Achromatopsia | Phase 1 / Phase 2 | Completed | MeiraGTx UK II Ltd | 11 | 2019-08-12 | 2022-12-01 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| ADVM-022 Intravitreal Gene Therapy for Wet AMD ADVM-022 - Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Adverum Biotechnologies, Inc. | 30 | 2018-11-14 | 2023-08-08 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
| Side Effects of Atropine (SEA) Study 0.01% concentration atropine drops - Myopia | Phase 1 / Phase 2 | Completed | Jeffrey J. Walline, OD PhD | 31 | 2018-07-23 | 2022-12-02 |
Showing 20 of 48. Sign in to see all of them.
Amblyopia (11) · Color Vision Defects (9) · Eye Diseases (9) · Retinal Diseases (7) · Retinitis Pigmentosa (6) · Usher Syndromes (6) · Eye Diseases, Hereditary (5) · Blindness (4) · Retinal Degeneration (4) · Anisometropia (3) · Eye Abnormalities (3) · Macular Degeneration (3) · Hemianopsia (2) · Leber Congenital Amaurosis (2)
Pathological Conditions, Signs and Symptoms (48) · Nervous System Diseases (47) · Signs and Symptoms (47) · Neurologic Manifestations (46) · Sensation Disorders (46) · Eye Diseases (39) · Brain Diseases (19) · Central Nervous System Diseases (19) · Eye Diseases, Hereditary (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Genetic Diseases, Inborn (14) · Ear Diseases (10) · Hearing Disorders (10) · Otorhinolaryngologic Diseases (10)
Transcranial Direct Current Stimulation (2) · Atropine (1) · Caffeine (1) · Dantrolene (1) · Docosahexaenoic Acids (1) · Donepezil (1) · Intravitreal Injections (1) · Ketoprofen (1) · Mycophenolic Acid (1) · Psilocybin (1) · Psychotherapy (1) · Ranibizumab (1) · Rituximab (1) · Robotics (1) · TPI-287 (1)
National Eye Institute (NEI) (4) · Johns Hopkins University (3) · University of California, San Francisco (3) · Beacon Therapeutics (2) · Boston Children's Hospital (2) · MeiraGTx UK II Ltd (2) · ProQR Therapeutics (2) · University of Magdeburg (2) · AAVantgarde Bio Srl (1) · Achelios Therapeutics (1) · Adverum Biotechnologies, Inc. (1) · Asalus Medical Instruments Limited (1) · BlueRock Therapeutics (1) · Capital Medical University (1) · City, University of London (1)
United States (34) · United Kingdom (5) · Australia (3) · Canada (3) · France (3) · Germany (3) · Austria (2) · Belgium (1) · Denmark (1) · India (1) · Iran (1) · Israel (1) · Italy (1)
Adam Boxer, MD, PhD (2) · David Jacobs, MD, MBA (2) · Agnes Wong, MD (1) · Anne Chiaramello, Ph.D. (1) · Ava K Bittner, OD, PhD (1) · Benedict Tan, MBBS, FRACP (1) · Bernhard A Sabel, Prof. Dr. (1) · Bharti Gangwani, MD (1) · Brian P Brooks, M.D. (1) · Carolyn Wu, MD (1) · Cha-Min Tang, PhD MD (1) · Courtney Kraus, MD (1) · Craig A Elmets (1)
PMID 17855283, PMID 20212198, PMID 22828504, PMID 23882695, PMID 24705452, PMID 25205868, PMID 26857842, PMID 28082176, PMID 30194931, PMID 30646425, PMID 30674731, PMID 31215818, PMID 31710340, PMID 32352493, PMID 33281736, PMID 33497524, PMID 34006508, PMID 34185708, PMID 34629400, PMID 37172884, PMID 37418643, PMID 38152412, PMID 38709228, PMID 40253438
2016 (2), 2018 (2), 2014 (1), R21DK113487 (1), R24EY022023 (1), UH3TR003897 (1)